Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study

Fig. 4

Consistency of the PCR-RDB HR-HPV genotyping assay and Cervista® HR-HPV assay in different age/cytology/pathology groups. CI, Confidence interval; 14HR-HPVs, 14 high-risk human papillomavirus types, containing HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68; Species 5/6 group, high-risk human papillomavirus species 5 and species 6, containing HPV-51, 56 and -66; Species 7 group, high-risk human papillomavirus species 7, containing HPV-18, -39, -45, -59 and -68; Species 9 group, high-risk human papillomavirus species 9, containing HPV-16, -31, -33, -35, -52 and -58; NILM, negative for intraepithelial lesion or malignancy; ASCUS/AGC, atypical squamous cells of undetermined significance/atypical glandular cells; LSIL, low-grade squamous intraepithelial lesion, i.e., CIN1; ≥ HSIL/ASC-H, high-grade squamous intraepithelial lesion or worse/atypical squamous cells without excluding high-grade squamous intraepithelial lesion; , Kappa value; , 95% confidence interval for the kappa value

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us